Reuters logo
BRIEF-Corbus Pharma reports improvement in skin conditions in a mid-stage study
November 6, 2017 / 1:57 PM / 13 days ago

BRIEF-Corbus Pharma reports improvement in skin conditions in a mid-stage study

Nov 6 (Reuters) - Corbus Pharmaceuticals Holdings Inc

* Corbus Pharmaceuticals reports significant improvement in mRSS and other clinical outcomes at 28-weeks in systemic sclerosis open-label extension of phase 2 study

* Corbus Pharmaceuticals Holdings Inc - ‍Company on track to commence phase 3 study Q4 2017​

* Corbus Pharmaceuticals Holdings Inc - Were no severe or serious adverse events and no clinically significant laboratory abnormalities related to drug​

* Corbus Pharmaceuticals - “‍Our focus now is to ensure successful execution of our phase 3 study, and we are on track to commence this before year end”​ Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below